These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Foged C Ther Deliv; 2011 Aug; 2(8):1057-77. PubMed ID: 22826868 [TBL] [Abstract][Full Text] [Related]
10. Increasing cellular immunogenicity to peptide-based vaccine candidates using a fluorocarbon antigen delivery system. Francis JN; Thaburet JF; Bonnet D; Sizer PJ; Brown CB; Georges B Vaccine; 2015 Feb; 33(8):1071-6. PubMed ID: 25573036 [TBL] [Abstract][Full Text] [Related]
11. Oxidized Carbon Nanosphere-Based Subunit Vaccine Delivery System Elicited Robust Th1 and Cytotoxic T Cell Responses. Sawutdeechaikul P; Cia F; Bancroft G; Wanichwecharungruang S; Sittplangkoon C; Palaga T J Microbiol Biotechnol; 2019 Mar; 29(3):489-499. PubMed ID: 30691253 [TBL] [Abstract][Full Text] [Related]
12. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479 [TBL] [Abstract][Full Text] [Related]
13. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Lingnau K; Riedl K; von Gabain A Expert Rev Vaccines; 2007 Oct; 6(5):741-6. PubMed ID: 17931154 [TBL] [Abstract][Full Text] [Related]
14. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model. Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634 [TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related]
16. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens. Swaminathan G; Thoryk EA; Cox KS; Meschino S; Dubey SA; Vora KA; Celano R; Gindy M; Casimiro DR; Bett AJ Vaccine; 2016 Jan; 34(1):110-9. PubMed ID: 26555351 [TBL] [Abstract][Full Text] [Related]
17. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible? Marasini N; Kaminskas LM Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591 [TBL] [Abstract][Full Text] [Related]
18. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669 [TBL] [Abstract][Full Text] [Related]
19. PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Silva AL; Soema PC; Slütter B; Ossendorp F; Jiskoot W Hum Vaccin Immunother; 2016 Apr; 12(4):1056-69. PubMed ID: 26752261 [TBL] [Abstract][Full Text] [Related]
20. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]